In addition to various factors that modulate the EFR effect [26] (e.g., bradykinin, nitric oxide derivatives, prostaglandins, angiotensin-converting enzyme inhibitors, and vascular endothelial growth factor [VEGF]), ligand–receptor interactions have been introduced as an active tumor-targeting strategy [27]. Here, VEGFA is linked to neoplasm.